Eylea’s Global Net Sales Increase 20 Percent in Q1-2018

May 4, 2018: By Jon Swedien

Net sales for Eylea (aflibercept) across the globe rose to $1.61 billion in Q1-2018, up 20 percent compared with Q1-2017, Regeneron reported May 3.

Eylea’s net sales in the US in Q1-2018 were $984 million, a 15 percent increase compared with the same quarter from the prior year, Regeneron reported.

Bayer commercializes Eylea outside the US, where the anti-VEGF’s net sales for Q1-2018 were $624 million, a 29 percent increase compared with Q1-2017, Regeneron said.

Regeneron recognized nearly $248 million in Q1-2018 from its share of net profit from Eylea sales outside the US, the company said.

Eylea gained approval in March from China’s FDA for the treatment of visual impairment due to diabetic macular edema (DME).

In addition, Eylea in March met its 24-week primary endpoint in a Phase III trial evaluating the anti-VEGF as a treatment for moderately severe to severe nonproliferative diabetic retinopathy.

Regeneron’s total revenues for the quarter were $1.5 billion, a 15 percent increase compared with Q1-2017, the Tarrytown, New York, company reported.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023